In Brief: Vagistat-1
This article was originally published in The Tan Sheet
Executive Summary
Vagistat-1: Bristol-Myers Squibb's one-dose vaginal yeast infection treatment generates sales of $16 mil. in food, drug and mass merchandise outlets from its mid-April launch to Sept. 14, according to Chicago-based Information Resources, Inc. The brand recorded $10 mil. in sales its first two months on the market ("The Tan Sheet" July 28, p. 7). The top brand, J&J's Monistat 3, had sales of $64.4 mil. in the 52 weeks ended Sept. 14, followed by Monistat 7 ($55.5 mil.), Bayer's Femstat 3 ($44.8 mil.) and Schering-Plough's Gyne-Lotrimin 3 ($20.3 mil.), according to IRI. Vagistat-1 sales have surpassed sales for regular strength Gyne-Lotrimin ($13.6 mil.) and Bayer's value-priced Mycelex-7 ($12.6 mil.) and Mycelex-3 ($7.1 mil.)...